Last reviewed · How we verify
GW685698X containing magnesium stearate
GW685698X containing magnesium stearate is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | GW685698X containing magnesium stearate |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients. (PHASE1)
- Repeat Dose GW685698X With Magnesium Stearate, Excipient Bridging Study, In Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW685698X containing magnesium stearate CI brief — competitive landscape report
- GW685698X containing magnesium stearate updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GW685698X containing magnesium stearate
What is GW685698X containing magnesium stearate?
GW685698X containing magnesium stearate is a Small molecule drug developed by GlaxoSmithKline.
Who makes GW685698X containing magnesium stearate?
GW685698X containing magnesium stearate is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GW685698X containing magnesium stearate in?
GW685698X containing magnesium stearate is in Phase 1.